Recently a covalent CDK7 inhibitor THZ1 has been reported as a promising drug for different types of cancers such as small cell lung cancer (SCLC) by preferentially targeting super-enhancer-driven transcription factor genes including MYC family proto-oncogenes and neuroendocrine lineage-specific factors [15]. Here, MYC is linked to small cell lung carcinoma.